LOS ANGELES, Nov. 08, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services and a premier global developer of digital health solutions, today reported financial results for its third quarter of 2026.
LOS ANGELES, Nov. 08, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services and a premier global developer of digital health solutions, today reported financial results for its third quarter of 2026.
NEW YORK, Nov. 08, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Qfin Holdings, Inc. (NASDAQ: QFIN) between March 18, 2026 and August 25, 2026, inclusive (the “Class Period”), of the important November 30, 2026 lead plaintiff deadline.
NEW YORK, Nov. 08, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Webull Corporation (NASDAQ: BULL) between April 26, 2025 and October 6, 2026, both dates inclusive (the “Class Period”), of the important December 7, 2026 lead plaintiff deadline in the securities class action…
NEW YORK, Nov. 08, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of UP Fintech Holding Limited (NASDAQ: TIGR) between April 22, 2024 and June 2, 2026, both dates inclusive (the “Class Period”), of the important December 28, 2026 lead plaintiff deadline in the securities…
– In the largest long-term hypertension trial of an aldosterone synthase inhibitor to date, lorundrostat demonstrated sustained reduction in automated office systolic blood pressure (AOSBP) of 17.8 mmHg at Week 48 from Launch-HTN baseline –